[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"chronic-liver-disease-and-cirrhosis\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:chronic-liver-disease-and-cirrhosis":24},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,65,93,126],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":27,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100549328","hepatomir-cacld-study-100549328",false,"NCT06432582","hepatomiR cACLD Study","Assessment of a hepatomiR Cut-off for Predicting Specific Hepatic Decompensation Events in Advanced Chronic Liver Disease","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Chronic liver disease (more than 6 months)\n* LSM ≥ 10 kPa\n* Outpatient at the Clinical Department of Internal Medicine II, University Hospital St. Pölten\n* Signed patient consent form\n\nExclusion Criteria:\n\n* Age older than 18 years\n* Pregnancy\n* Primary hepatic malignancy (hepatocellular carcinoma, cholangiocarcinoma) with portal invasion and\u002For extrahepatic spread","ALL","18 Years",{"count":19,"type":20},156,"ESTIMATED","OBSERVATIONAL","This study looks to gather data on hepatomiR, a CE-certified test already intended for gauging liver-related outcomes, in order to define a cut-off regarding specific decompensation events (ascites, variceal hemorrhage, hepatic encephalopathy) in chronic liver disease (CLD). Based on these data, it is aimed to advance the current understanding of factors driving decompensation, with potential repercussions for future risk management and therapy.",[24,25,26],"Chronic Liver Disease and Cirrhosis","Chronic Liver Disease","Portal Hypertension",[28,29,30,31],"hepatomiR","micro-RNA","hepatic decompensation","ACLD","RECRUITING","2026-08-20",{"date":35,"type":36},"2026-08-21","ACTUAL",{"date":38,"type":36},"2024-05-15",{"date":40,"type":20},"2028-06",{"name":42,"class":43},"Karl Landsteiner University of Health Sciences","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":4,"eligibilityCriteria":51,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":54,"conditions":55,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":44},"100646995","influence-of-donor-and-recipient-genetic-polymorphisms-on-graft-steatosis-after-liver-transplant-100646995","NCT07685353","Influence of Donor and Recipient Genetic Polymorphisms on Graft Steatosis After Liver Transplant","Influence of Donor and Recipient PNPLA3 and MBOAT7 Gene Polymorphisms on Graft Liver Steatosis After Living Donor Liver Transplant for Metabolic Dysfunction-associated Steatohepatitis (MASH) Related Cirrhosis","Inclusion Criteria:\n\n* All LDLT recipients with MASH related CLD and their donors who underwent their surgery at ILBS at least 3 years prior to the onset of this study.\n\nExclusion Criteria:\n\n* Pediatric (\\\u003C18 years)\n* Transplants for ALF\u002F ACLF",{"count":53,"type":20},50,"MASH (Metabolic Dysfunction-associated Steatohepatitis) is among the most common indications for liver transplantation.The metabolic syndrome persists after liver transplant and is often further exacerbated among MAFLD patients, thereby leading to recurrence of MAFLD in the allograft. MAFLD is a complex phenotype, dynamic interactions between both genetic and environmental factors are likely to shape disease susceptibility and progression.\n\nGenetic and epidemiological studies, indicates strong heritability of hepatic fat content.Family studies demonstrate that first degree relatives of patients with MAFLD are at a much higher risk of the disease than the general population.Most of the data available is regarding Deceased Donor Liver Transplant and Western population.Most studies have studied single gene variant but fatty liver is a polygenic trait.No study was done exclusively in MASH recipients.\n\nIn this study we aim to study the effect of recipient and donor PNPLA3, MBOAT7 gene variations, and other clinical \\& laboratory data on graft liver steatosis in liver transplant recipients. We also propose to compare the outcomes of genetically related donors vs unrelated donors, to know the influence of genetic factors vis-a-vis environmental factors.",[24],"2026-07-20",{"date":58,"type":36},"2026-07-21",{"date":60,"type":36},"2026-07-07",{"date":62,"type":20},"2026-10-31",{"name":64,"class":43},"Institute of Liver and Biliary Sciences, India",{"id":66,"slug":67,"hasResults":11,"nctId":68,"briefTitle":69,"officialTitle":70,"acronym":4,"eligibilityCriteria":71,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":72,"enrollmentInfo":73,"targetDuration":4,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":88,"completionDateStruct":90,"leadSponsor":92,"locationsCount":44},"100647783","magnetic-resonance-cholangiopancreatography-in-living-liver-donors-and-its-relationship-with-post-operative-recipient-biliary-complications-100647783","NCT07715500","Magnetic Resonance Cholangiopancreatography in Living Liver Donors and Its Relationship With Post Operative Recipient Biliary Complications","Magnetic Resonance Cholangiopancreatography in Living Liver Donors and Its Relationship With Post Operative Recipient Biliary Complications - Open Label Randomised Controlled Trial","Inclusion Criteria:\n\n* All prospective voluntary healthy liver donor of age 18-55\n\nExclusion Criteria:\n\n* Type C\u002FD Portal vein anatomy\n* Left sided Gallbladder\n* Right Posterior Graft\n* Recipients undergoing Hepaticojejunostomy","55 Years",{"count":74,"type":20},100,"INTERVENTIONAL",[77],"NA","Living donor liver transplantation is widely accepted as an life-saving treatment for patients with end-stage liver diseases. Careful donor selection is essential to maximize the success and minimize the risk of postoperative complications in donors and recipients. Mapping of biliary anatomy is one of the critical assessments for donor selection and surgical planning ,Biliary reconstruction is considered as the \"Achilles heel\" of liver transplantation and adequate imaging assessment of biliary anatomy can largely benefit the biliary anastomosis. Preoperative imaging assessment of biliary anatomy is good for the selection of donors but may not indispensable for surgical planning and Intraoperative confirmative assessment of biliary anatomy with IOC was essential",[24,80,81],"Liver Transplant; Complications","Donor Hepatectomy",[83,84,85],"Liver Transplantation","Magnetic Resonance Cholangiopancreatography","Liver donors","2026-07-16",{"date":56,"type":36},{"date":89,"type":36},"2025-07-01",{"date":91,"type":20},"2026-08-30",{"name":64,"class":43},{"id":94,"slug":95,"hasResults":11,"nctId":96,"briefTitle":97,"officialTitle":97,"acronym":98,"eligibilityCriteria":99,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":102,"conditions":103,"keywords":110,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":44},"100415541","constitution-of-a-biological-collection-to-establish-preclinical-translational-models-for-the-study-of-tumors-and-chronic-liver-diseases-100415541","NCT04690972","\"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases\".","LivMOD","Inclusion Criteria:\n\n1. Patients\n\n   * diagnosed with chronic liver disease (viral or not)\n   * diagnosed with at least one liver nodule for which a biopsy is planned as part of the care\n   * for hepatobiliary surgery planned as part of care\n   * for locoregional treatment for HCC is indicated\n2. Patients able to receive and understand information relating to the study and give their written informed consent\n3. Patients affiliated to the French social security system\n\nExclusion Criteria:\n\n1. Minor patients\n2. Patients under legal protection,\n3. Patients subject to legal protection or unable to express their consent,\n4. Patients in a situation of social fragility,\n5. Pregnant or breastfeeding woman,\n6. No signing of informed consent.",{"count":101,"type":20},800,"Development of preclinical translational models for chronic liver tumors and diseases study, such as spheroids cultured in autologous medium and murine xenograft models to test the efficacy of new therapeutic strategies.",[24,104,105,106,107,108,109],"Liver Cancer","Non-Alcoholic Fatty Liver Disease","Non-Alcoholic Steatohepatitis","Viral Hepatitis B","Viral Hepatitis C","Viral Hepatitis D",[111,112,113,114,115],"Liver disease","Ex vivo models","Single cell","Biomarkers","Spheroïds","2026-02-10",{"date":118,"type":36},"2026-02-12",{"date":120,"type":36},"2021-01-14",{"date":122,"type":20},"2029-09-02",{"name":124,"class":125},"Institut National de la Santé Et de la Recherche Médicale, France","OTHER_GOV",{"id":127,"slug":128,"hasResults":11,"nctId":129,"briefTitle":130,"officialTitle":130,"acronym":4,"eligibilityCriteria":131,"healthyVolunteers":11,"sex":132,"minAge":17,"maxAge":133,"enrollmentInfo":134,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":135,"conditions":136,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":137,"lastUpdatePostDateStruct":138,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":44},"100613561","impact-of-liver-transplantation-on-sexual-life-and-function-100613561","NCT07268196","Impact of Liver Transplantation on Sexual Life and Function","Inclusion Criteria:\n\n1. Married male Patients.\n2. Decompensated Chronic Liver Disease awaiting elective liver transplantation.\n3. Post Liver Transplant patients with stable graft function.\n\nExclusion Criteria:\n\n1. Negative consent.\n2. Patients with ongoing medical and surgical issues (biliary complications, graft complication etc.).\n3. Acute on Chronic Liver Failure and Acute Liver Failure patients.","MALE","60 Years",{"count":74,"type":20},"Liver Transplantation (LT) is a lifesaving intervention with around 90% of recipients currently surviving the first postoperative year and subsequent life expectancy now exceeding 20 years. After the post-operative recovery period, however, LT recipients become more and more confronted with the challenges of re-engagement with life after transplantation, a need to reach a new stability, reestablish function in everyday life, reconnect with valued roles, regain independence, and resume work Sexual function is a very important parameter in the evaluation of Quality of Life (QoL), as it has been shown that sexual dysfunction in transplant patients is associated with increased depression and decreased QoL. There are several studies in the relevant literature supporting the recovery of sexual function in patients after liver transplantation. It has been found that recovery was observed in erectile dysfunction in male patients 6 months after liver transplantation.",[24],"2025-12-24",{"date":139,"type":36},"2025-12-31",{"date":141,"type":36},"2025-12-07",{"date":143,"type":20},"2026-10-23",{"name":64,"class":43}]